Aflibercept‑Jbvf 2 mg/0.05 mL per injection Suppliers & Bulk Manufacturers
Available Forms: Intravitreal injection (liquid solution)
Available Strengths: 2 mg/0.05 mL per injection
Reference Brands: Eylea; Yesafili- biosimilar of Eylea
Category: Opthalmology
Yesafili, a biosimilar of Eylea, inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. It treats age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Benefits include similar efficacy to Eylea, lower costs, and improved access to vital eye therapies.
Product Description:
Yesafili, a biosimilar of Eylea (aflibercept), is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality according to GMP standards. In the US, FDA approval requires extensive comparability data, validation, and clinical validation. In the EU, CE marking certifies conformity under MDR standards. These biosimilars undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical trial results, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality ophthalmic biosimilars for eye disease management worldwide.
Aflibercept‑Jbvf — third party manufacturing & bulk supply
Aflibercept‑Jbvf 2 mg/0.05 mL per injection is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Aflibercept‑Jbvf listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Aflibercept‑Jbvf →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Aflibercept‑jbvf is used to treat eye conditions caused by abnormal blood vessel growth, such as wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. It works by inhibiting vascular endothelial growth factor (VEGF) to prevent new blood vessel formation and reduce fluid leakage in the retina.
The active ingredient is aflibercept, a recombinant fusion protein that binds VEGF-A, VEGF-B, and placental growth factor (PlGF). It is formulated as a sterile solution for intravitreal injection.
The trade name for this biosimilar is Aflibercept‑jbvf, and the reference product is Eylea®.
Aflibercept‑jbvf is manufactured by licensed biopharmaceutical companies producing approved biosimilars, in accordance with GMP standards, globally.
The generic name is Aflibercept.
Brand examples include Aflibercept‑jbvf and Eylea® (reference product).
Related Products
Artificial Tears
Strength:
0.3% to 1%
Form: Eye Drops/ Eye Gel/ Eye ointment
Reference Brands: Refresh Tears (USA/LATAM), Hylo-Tear (EU), Refresh Liquigel (India)
View Details
Tetrahydrozoline Hydrochloride
Strength:
0.05%
Form: Eye Drops
Reference Brands: Visine (USA/EU / LATAM), Ocuvis (India)
View Details
Quick Response Guaranteed | Verified Suppliers
